The evaluation in the efficacy of Radium-223 for overall survival among patients with mCRPC: A meta-analysis 首頁 / 最新消息 / The evaluation in the efficacy of Radium-223 for overall survival among patients with mCRPC: A meta-analysis Publications 2024-08-16 Yen-Hsiang Chang1, Hao-Lun Luo2, Li-Yu Chen3, Shiang-Ling Lin3, Ya-Ting Huang3 1Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan 2Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan 3Primo Biotechnology Co., Ltd, Taipei, Taiwan This meta-analysis was presented at the 2024 Annual Meeting of the Taiwan Urological Association(2024 TUA). Radium-223 is the first FDA-approved bone-targeting internal alpha particle-emitting radiotherapeutic agent and helps to delay symptomatic skeletal events and significantly improve quality of life. Several studies have shown that radium-223 can effectively improve overall survival. According to this meta-analysis, mCRPC patients who underwent 5-6 cycles of radium-223 treatment or combine it with androgen deprivation therapy (ADT) or chemotherapy (C/T) experienced improvements in overall survival. Although a significant difference in overall survival between radium-223 and placebo has not yet been observed, these analysis results still offer valuable insights for prostate cancer treatment.
